PH94B：新興薬剤の考察と市場予測（2032年）

当レポートでは、主要7市場（米国・ドイツ・フランス・イタリア・スペイン・英国・日本）の全般性不安障害（GAD）に対するPH94B市場について調査分析し、作用機序、用法と用量、研究開発についての考察や、市場予測などの情報を提供しています。

目次

第1章 レポートのイントロダクション

第2章 全般性不安障害におけるPH94Bの概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 治験情報
  • 安全性と有効性
• 規制のマイルストーン
• その他の開発活動
• 製品プロファイル

第3章 競合情勢（後期の新しい治療法）

第4章 PH94B市場の評価

• 全般性不安障害におけるPH94B市場の展望
• 主要7市場分析
  • 主要7市場の全般性不安障害に対するPH94Bの市場規模
• 市場分析：国別
  • 米国の全般性不安障害に対するPH94Bの市場規模
  • ドイツの全般性不安障害に対するPH94Bの市場規模
  • 英国の全般性不安障害に対するPH94Bの市場規模

第5章 SWOT分析

第6章 アナリストの見解

第7章 付録

第8章 DelveInsightのサービス内容

第9章 免責事項

第10章 DelveInsightについて

第11章 レポート購入オプション

List of Tables

• Table 1: PH94B, Clinical Trial Description, 2023
• Table 2: PH94B, General Description
• Table 3: Competitive Landscape (Emerging Therapies)
• Table 4: PH94B Market Size in the 7MM, in USD million (2019-2032)
• Table 5: PH94B Market Size in the US, in USD million (2019-2032)
• Table 6: PH94B Market Size in Germany, in USD million (2019-2032)
• Table 7: PH94B Market Size in France, in USD million (2019-2032)
• Table 8: PH94B Market Size in Italy, in USD million (2019-2032)
• Table 9: PH94B Market Size in Spain, in USD million (2019-2032)
• Table 10: PH94B Market Size in the UK, in USD million (2019-2032)
• Table 11: PH94B Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: PH94B Market Size in the 7MM, USD million (2019-2032)
• Figure 2: PH94B Market Size in the United States, USD million (2019-2032)
• Figure 3: PH94B Market Size in Germany, USD million (2019-2032)
• Figure 4: PH94B Market Size in France, USD million (2019-2032)
• Figure 5: PH94B Market Size in Italy, USD million (2019-2032)
• Figure 6: PH94B Market Size in Spain, USD million (2019-2032)
• Figure 7: PH94B Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: PH94B Market Size in Japan, USD million (2019-2032)

"PH94B Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about PH94B for Generalized Anxiety Disorder (GAD) in the seven major markets. A detailed picture of the PH94B for Generalized Anxiety Disorder in the 7MM, i.e., the United States, EU4 (Germany, France, Italy and Spain) and the United Kingdom, and Japan for the study period 2019-2032 is provided in this report along with a detailed description of the PH94B for Generalized Anxiety Disorder. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the PH94B market forecast, analysis for Generalized Anxiety Disorder in the 7MM descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Generalized Anxiety Disorder.

Drug Summary:

VistaGen's PH94B is an innovative synthetic investigational neurosteroid developed from proprietary compounds called pherines. With its novel mechanism of action, PH94B is an odorless nasal spray administered at microgram-level doses to achieve rapid-onset of anti-anxiety, or anxiolytic, effects. The pharmacological activity of PH94B is fundamentally different from that of all FDA-approved anti-anxiety drugs. Importantly, PH94B does not require systemic uptake and distribution to produce its rapid-onset anti-anxiety effects. In all clinical trials to date, PH94B's safety profile has been excellent, with placebo-like side effects and no serious adverse events like those that are associated with the current FDA-approved treatment options.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the PH94B description, mechanism of action, dosage and administration, research and development activities in Generalized Anxiety Disorder.
• Elaborated details on PH94B regulatory milestones and other development activities have been provided in this report.
• The report also highlights the PH94B research and development activity in Generalized Anxiety Disorder in detail across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around PH94B.
• The report contains forecasted sales of PH94B for Generalized Anxiety Disorder till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Generalized Anxiety Disorder.
• The report also features the SWOT analysis with analyst views for PH94B in Generalized Anxiety Disorder.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

PH94B Analytical Perspective by DelveInsight

• In-depth PH94B Market Assessment

This report provides a detailed market assessment of PH94B in Generalized Anxiety Disorder in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data of PH94B.

• PH94B Clinical Assessment

The report provides the clinical trials information of PH94B in Generalized Anxiety Disorder covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Generalized Anxiety Disorder is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence PH94B dominance.
• Other emerging products for Generalized Anxiety Disorder are expected to give tough market competition to PH94B and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of PH94B in Generalized Anxiety Disorder.
• Our in-depth analysis of the forecasted sales data of PH94B will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the PH94B in Generalized Anxiety Disorder.  

Key Questions

• What is the product type, route of administration and mechanism of action of PH94B?
• What is the clinical trial status of the study related to PH94B in Generalized Anxiety Disorder and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the PH94B development?
• What are the key designations that have been granted to PH94B for Generalized Anxiety Disorder?
• What is the forecasted market scenario of PH94B for Generalized Anxiety Disorder?
• What are the forecasted sales of PH94B in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available in Generalized Anxiety Disorder and how are they giving competition to PH94B for Generalized Anxiety Disorder?
• Which are the late-stage emerging therapies under development for the treatment of Generalized Anxiety Disorder?

Table of Contents

1. Report Introduction

2. PH94B Overview in Generalized Anxiety Disorder

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Regulatory milestones
• 2.4. Other Developmental Activities
• 2.5. Product Profile

3. Competitive Landscape (Late-stage Emerging Therapies)

4. PH94B Market Assessment

• 4.1. Market Outlook of PH94B in Generalized Anxiety Disorder
• 4.2. 7MM Market Analysis
  • 4.2.1. Market size of PH94B in the 7MM for Generalized Anxiety Disorder
• 4.3. Country-wise Market Analysis
  • 4.3.1. Market size of PH94B in the United States for Generalized Anxiety Disorder
  • 4.3.2. Market size of PH94B in Germany for Generalized Anxiety Disorder
  • 4.3.3. Market size of PH94B in France for Generalized Anxiety Disorder
  • 4.3.4. Market size of PH94B in Italy for Generalized Anxiety Disorder
  • 4.3.5. Market size of PH94B in Spain for Generalized Anxiety Disorder
  • 4.3.6. Market size of PH94B in the United Kingdom for Generalized Anxiety Disorder
  • 4.3.7. Market size of PH94B in Japan for Generalized Anxiety Disorder

5. SWOT Analysis

6. Analysts' Views

7. Appendix

• 7.1. Bibliography
• 7.2. Report Methodology

8. DelveInsight Capabilities

9. Disclaimer

10. About DelveInsight

11. Report Purchase Options